.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,217,430

« Back to Dashboard

Claims for Patent: 7,217,430

Title:Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan
Abstract:Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.
Inventor(s): Storm; Kevin H. (Bristol, TN), Conley; Creighton P. (Bristol, TN), Roush; John A. (Kingsport, TN)
Assignee: Beecham Pharmaceuticals (Pte) Limited (Jurong, SG)
Application Number:10/870,818
Patent Claims: 1. A composition comprising amoxicillin and potassium clavulanate in a dosage of 2000 mg of amoxicillin and 125 mg of potassium clavulanate, wherein the composition is in a solid form and comprises a first release phase and a second release phase; the first release phase comprising potassium clavulanate and a first amount of the amoxicillin; and the second release phase comprising a second amount of the amoxicillin in the form of a soluble salt at about 60 80% of the second phase, a pharmaceutically acceptable organic acid in a molar ratio of 50:1 to 1:5 (amoxicillin to organic acid), and a reduced amount of a pharmaceutically acceptable release retarding polymer which is xanthan gum at about 1 5% of the second phase; wherein the composition provides a mean maximum plasma concentration (Cmax) of amoxicillin of at least 12 .mu.g/ml.

2. A composition according to claim 1 wherein the xanthan gum is pharmaceutical grade xanthan gum, 200 mesh.

3. A composition according to claim 1 wherein the amoxicillin in the first release phase is amoxicillin trihydrate.

4. A composition according to claim 1 wherein the soluble salt of amoxicillin in the second release phase is sodium amoxicillin.

5. A composition according to claim 4 wherein the sodium amoxicillin is crystallized sodium amoxicillin.

6. A composition according to claim 1 wherein the composition provides an Area under the Curve (AUC) value of amoxicillin which is at least 80% of that of the same amount if taken as an immediate release formulation over the same dosage period.

7. A composition according to claim 1 wherein the composition provides a mean plasma concentration of amoxicillin of at least 4 .mu.g/ml for at least 4.4 hours.

8. A composition according to claim 1 wherein the ratio of amoxicillin in the first and second release phases is from 3:1 to 1:3.

9. A composition according to claim 1 wherein the ratio of amoxicillin in the first and second release phases is from 3:1 to 2:3.

10. A composition according to claim 1 wherein the ratio of amoxicillin in the first and second release phases is from 2:1 to 2:3.

11. A composition according to claim 1 wherein the ratio of amoxicillin in the first and second release phases is from 3:2 to 1:1.

12. A composition according to claim 1 wherein the solid form is a tablet.

13. A composition according to claim 12 wherein the tablet is a bilayer tablet.

14. A composition according to claim 1 wherein the first release phase comprises essentially all the potassium clavulanate.

15. A composition according to claim 1 wherein the release of amoxicillin has a biphasic profile.

16. A method for treating a bacterial infection in a patient in need thereof comprising administering to said patient an effective amount of a formulation according to claim 1.

17. A method according to claim 16 in which the bacterial infection is caused by at least one of the organisms S. pneumoniae, H. influenzae, and M. catarrhalis.

18. A method according to claim 17 wherein the S. pneumoniae are Drug Resistant S. pneumoniae and Penicillin Resistant S. pneumoniae organisms.

19. A method according to claim 16 wherein the bacterial infection is a respiratory tract infection.

20. A method according to claim 19 wherein the respiratory tract infection is community acquired pneumoniae (CAP), acute exacerbation of chronic bronchitis (AECB), or acute bacterial sinusitis (ABS).

21. A method according to claim 16 wherein the formulation is administered over 7 to 14 days.

22. The composition of claim 1 wherein the pharmaceutically acceptable organic acid is in a molar ratio of 20:1 to 1:2 (amoxicillin to organic acid).

23. The composition of claim 1 wherein the pharmaceutically acceptable organic acid is selected from mono-carboxylic acids and poly-carboxylic acids having from 2 to 25 carbon atoms, monocyclic and polycyclic aryl acids, and monohydrogen, dihydrogen metal salts of multi-valent acids.

24. The composition of claim 23 wherein the pharmaceutically acceptable organic acid is selected from malonic acid, succinic acid, fumaric acid, maleic acid, adipic acid, lactic acid, levulinic acid, sorbic acid, or a fruit acid such as tartaric acid, malic acid, ascorbic acid, and citric acid.

25. The composition of claim 24 wherein the pharmaceutically acceptable organic acid is citric acid.

26. The composition of claim 25 wherein the sodium amoxicillin and citric acid are in a molar ratio of 20:1 to 1:2.

27. The composition of claim 26 wherein the sodium amoxicillin is about 438 mg .+-.5%, citric acid is about 78 mg .+-.10%, and xanthan gum is about 2% by weight.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc